{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Cellectar Biosciences, Inc.
Is Cellectar Biosciences, Inc. technically bullish or bearish?
As of June 20, 2025, the technical trend is mildly bearish due to daily moving averages indicating bearish sentiment, despite mixed signals from weekly and monthly indicators.
Who are in the management team of Cellectar Biosciences, Inc.?
As of March 2022, Cellectar Biosciences, Inc.'s management team includes Mr. Douglas Swirsky (Independent Chairman), Mr. James Caruso (President and CEO), and five Independent Directors: Mr. Frederick Driscoll, Dr. Stephen Hill, Mr. Stefan Loren, and Mr. John Neis. This team combines key executives with independent oversight for structured leadership.
What does Cellectar Biosciences, Inc. do?
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments, with a market cap of $16.19 million and a recent net profit loss of $7 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.
How big is Cellectar Biosciences, Inc.?
As of Jun 18, Cellectar Biosciences, Inc. has a market capitalization of 16.19 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -24.54 million over the latest four quarters. The company reported shareholder's funds of 15.68 million and total assets of 25.47 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
